ES2640572T3 - Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas - Google Patents

Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas Download PDF

Info

Publication number
ES2640572T3
ES2640572T3 ES12719541.0T ES12719541T ES2640572T3 ES 2640572 T3 ES2640572 T3 ES 2640572T3 ES 12719541 T ES12719541 T ES 12719541T ES 2640572 T3 ES2640572 T3 ES 2640572T3
Authority
ES
Spain
Prior art keywords
agent
solvent
hcl
agents
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12719541.0T
Other languages
English (en)
Spanish (es)
Inventor
Borje S. Andersson
Jeffrey Tarrand
Benigno C. Valdez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Platform Brightworks Two Ltd
Original Assignee
Platform Brightworks Two Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Platform Brightworks Two Ltd filed Critical Platform Brightworks Two Ltd
Application granted granted Critical
Publication of ES2640572T3 publication Critical patent/ES2640572T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES12719541.0T 2011-04-28 2012-04-20 Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas Active ES2640572T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161480259P 2011-04-28 2011-04-28
US201161480259P 2011-04-28
PCT/US2012/034361 WO2012148799A1 (en) 2011-04-28 2012-04-20 Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

Publications (1)

Publication Number Publication Date
ES2640572T3 true ES2640572T3 (es) 2017-11-03

Family

ID=46045121

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12719541.0T Active ES2640572T3 (es) 2011-04-28 2012-04-20 Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas
ES17175794T Active ES2822350T3 (es) 2011-04-28 2012-04-20 Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17175794T Active ES2822350T3 (es) 2011-04-28 2012-04-20 Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas

Country Status (15)

Country Link
US (5) US9364433B2 (enExample)
EP (2) EP3238709B1 (enExample)
JP (2) JP6080312B2 (enExample)
CN (2) CN103635179B (enExample)
AR (1) AR086115A1 (enExample)
AU (1) AU2012250050B2 (enExample)
CA (1) CA2834262C (enExample)
DK (2) DK2701684T3 (enExample)
ES (2) ES2640572T3 (enExample)
HU (2) HUE034480T2 (enExample)
IL (1) IL229067B (enExample)
MX (2) MX380805B (enExample)
PL (2) PL2701684T3 (enExample)
TW (1) TWI626059B (enExample)
WO (1) WO2012148799A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CN102686205A (zh) 2009-10-02 2012-09-19 弗艾米克斯有限公司 局部四环素组合物
RU2734128C2 (ru) * 2010-12-16 2020-10-13 Плэтформ Брайтворкс Ту,Лтд Фармацевтические препараты азолов для парентерального введения и способы их получения и применения для лечения заболеваний, чувствительных к азольным соединениям
CN103635179B (zh) * 2011-04-28 2017-12-29 普拉福姆五金器具第二有限公司 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法
US20140178479A1 (en) * 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
GR20120100242A (el) * 2012-05-04 2014-01-02 Micrel Ιατρικα Μηχανηματα Α.Ε., Αντλια και προγεμισμενος ασκος/σετ αναλγησιας
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3045169B1 (en) 2013-09-13 2018-05-02 Akiko Itai Aqueous solution formulation, and manufacturing method for same
CN105939699B (zh) 2013-12-03 2020-10-02 西北大学 脂质体颗粒、制备所述脂质体颗粒的方法以及其用途
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US11696883B2 (en) 2014-05-23 2023-07-11 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth
CA2903734C (en) 2014-05-23 2016-03-01 Houfar SEKHAVAT Compositions for reducing hair loss and/or increasing hair regrowth
US10434064B2 (en) 2014-06-04 2019-10-08 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CN105394045B (zh) * 2014-09-04 2020-02-14 中国科学院上海巴斯德研究所 一种肠道病毒的小分子化合物抑制剂及其应用
US11266621B1 (en) 2014-10-02 2022-03-08 Exela Sterile Medicines Llc Methocarbamol composition and related methods
WO2016059590A1 (en) * 2014-10-16 2016-04-21 Piramal Enterprises Limited Stable injectable composition of small molecule drugs and process for its preparation
TWI516520B (zh) 2014-10-31 2016-01-11 財團法人工業技術研究院 波長轉換聚合物、其製法及包含其之波長轉換裝置
EP3347009B1 (en) 2015-07-08 2021-10-13 Triple Hair Inc. Composition comprising resveratrol and melatonin for reducing hair loss and/or increasing hair regrowth
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US20170239250A1 (en) 2016-02-19 2017-08-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CN105837556B (zh) * 2016-04-11 2018-10-26 上海工程技术大学 一种来那度胺与烟酰胺共晶的制备方法
ES2937307T3 (es) 2016-07-26 2023-03-27 Univ Southern California Inhibición selectiva del bromodominio del BDF1 fúngico
WO2018042352A1 (en) * 2016-08-31 2018-03-08 Taro Pharmaceutical Industries Fenoldopam topical formulations for treating skin disorders
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
CN106841100A (zh) * 2016-12-28 2017-06-13 北京医药集团有限责任公司 一种基于近红外光谱技术的小规格口服固体制剂中活性药物成分快速测定方法
MA48047A (fr) * 2017-04-05 2020-02-12 Modernatx Inc Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée
CA3059435A1 (en) * 2017-04-12 2018-10-18 Synergistic Therapeutics, Llc Therapeutic neuropathic pain lotion
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. RNA FORMULATIONS
CN111315359A (zh) 2017-08-31 2020-06-19 摩登纳特斯有限公司 制备脂质纳米颗粒的方法
WO2020061457A1 (en) 2018-09-20 2020-03-26 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
EP3866783A4 (en) * 2018-10-16 2022-08-03 US Nano Food & Drug Inc INTRATUMOR INJECTION FORMULATION
WO2020087031A1 (en) 2018-10-26 2020-04-30 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
US20210369669A1 (en) * 2018-10-31 2021-12-02 Systamedic Inc. Autophagy activators and inhibitors of ferroptosis for preventing acute renal failure and neurotoxcity induced by certain antibiotics
CN109627148B (zh) * 2018-11-28 2021-09-03 中国农业科学院麻类研究所 一种大麻二酚的制备方法、制得的大麻二酚及其用途
BR112021017140A2 (pt) 2019-03-08 2021-11-09 Taro Pharma Ind Composições tópicas estáveis de fenoldopam
CN113874502A (zh) 2019-03-11 2021-12-31 摩登纳特斯有限公司 补料分批体外转录方法
US20220387416A1 (en) * 2019-10-25 2022-12-08 Cmc Pharmaceuticals, Inc. Atropine-scopolamine with enhanced stability
JP2023505189A (ja) * 2019-12-04 2023-02-08 レスク ファーマシューティカルズ エルエルシー 経口利尿薬に不応性の浮腫を処置するための方法及び組成物
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
CN114181211B (zh) * 2020-09-14 2024-05-28 鲁南制药集团股份有限公司 一种酮咯酸与苯甲酰胺共晶体及其制备方法
CN112697945A (zh) * 2020-12-18 2021-04-23 卓和药业集团有限公司 泊沙康唑肠溶片含量的分析方法
CN113274379B (zh) * 2021-05-25 2023-04-25 湖北工业大学 Bephenium Hydroxynaphthoate在制备抗EV71药物的应用
CN113768937B (zh) * 2021-11-15 2022-04-08 恒翼生物医药科技(上海)有限公司 用于降低尿酸水平的化合物
MX2024008162A (es) * 2021-12-27 2024-09-17 Enalare Therapeutics Inc Formulaciones parenterales estimulantes respiratorias.
CN115721607B (zh) * 2022-11-19 2023-07-21 华夏生生药业(北京)有限公司 一种乳酸左氧氟沙星注射液及其制备方法
US20250032417A1 (en) 2023-07-24 2025-01-30 Hyloris Developments Sa Lyophilized metolazone formulation for parenteral administration
WO2025054148A1 (en) * 2023-09-07 2025-03-13 Cfd Research Corporation Co-administration of astemizole and an anticancer agent to treat cancer
CN118121554A (zh) * 2024-03-14 2024-06-04 天津市保灵动物保健品有限公司 盐酸特比萘芬片剂
CN119499175A (zh) * 2024-11-23 2025-02-25 江西赣南海欣药业股份有限公司 一种注射用法莫替丁及其制备方法
CN119951294B (zh) * 2025-02-14 2025-12-16 内蒙古优然牧业有限责任公司 一种用于牧场的生物除臭剂及其制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS475827Y1 (enExample) 1970-04-02 1972-02-29
JPS475827A (enExample) * 1971-08-27 1972-03-29
AU461715B2 (en) * 1972-01-21 1975-05-19 American Home Products Corporation Parenteral benzodiazepine compositions
DE3316510A1 (de) 1983-05-06 1984-11-08 Bayer Ag Parenterale formulierung von nimodipin, ein verfahren zu ihrer herstellung sowie ihre verwendung bei der bekaempfung von erkrankungen
US4912124A (en) 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
DE3702105A1 (de) 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
JPH01242525A (ja) 1988-03-25 1989-09-27 Nippon Nohyaku Co Ltd 抗真菌外用剤
US5430057A (en) * 1993-09-30 1995-07-04 Board Of Regents, The University Of Texas System Parenteral busulfan for treatment of malignant disease
US5869474A (en) * 1997-05-16 1999-02-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Low dosage treatment for cocaine craving and withdrawal
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US7179475B1 (en) 1998-12-04 2007-02-20 Johnson & Johnson Consumer Companies, Inc. Anhydrous topical skin preparations
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
AU5273200A (en) * 1999-05-24 2000-12-12 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
CN1174741C (zh) * 1999-09-21 2004-11-10 Rtp药品公司 生物活性物质的表面改性微粒组合物
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
GB2365770B (en) 2000-08-18 2002-07-31 Diomed Dev Ltd Antifungal ketoconazole composition for topical use
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030072807A1 (en) 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
JP2002322056A (ja) 2001-04-27 2002-11-08 Nippon Kayaku Co Ltd トリアゾール誘導体の溶液製剤
US20050191359A1 (en) * 2001-09-28 2005-09-01 Solubest Ltd. Water soluble nanoparticles and method for their production
US6878693B2 (en) 2001-09-28 2005-04-12 Solubest Ltd. Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
US6991800B2 (en) 2002-06-13 2006-01-31 Vicuron Pharmaceuticals Inc. Antifungal parenteral products
AU2003249510A1 (en) 2002-08-12 2004-02-25 Ranbaxy Laboratories Limited A parenteral dosage form of selective cox-2 inhibitors
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US9259390B2 (en) * 2003-08-13 2016-02-16 The University Of Houston System Parenteral and oral formulations of benzimidazoles
GB0412866D0 (en) 2004-06-09 2004-07-14 Novartis Ag Organic compounds
FR2872703B1 (fr) 2004-07-07 2006-10-06 Ethypharm Sa Nanoparticules polymeriques composites
US20060116404A1 (en) 2004-09-24 2006-06-01 Gary Robinson CAI-based systems and methods for the localized treatment of ocular and other diseases
JP2008534610A (ja) 2005-03-31 2008-08-28 ブリストル−マイヤーズ スクイブ カンパニー イクサベピロンの投与方法
CA2613389A1 (en) 2005-06-27 2007-01-04 Barrier Therapeutics, Inc. Micogel topical formulations
ITMI20051826A1 (it) 2005-09-29 2007-03-30 Novachem S A Kit per la somministrazione parenterale di medicamenti
WO2007047253A2 (en) 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
CA2626016A1 (en) 2005-10-21 2007-06-21 Panacea Biotec Limited Pharmaceutical composition comprising at least one anticancer drug and at least one polymer
AU2007206582B2 (en) 2006-01-23 2011-09-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Microspheres comprising nanocapsules containing a lipophilic drug
US20070249546A1 (en) * 2006-04-22 2007-10-25 Sawaya Assad S Ophthalmic and related aqueous solutions containing antifungal agents, uses therefor and methods for preparing them
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
AU2007355106A1 (en) 2006-11-29 2008-12-18 Foamix Ltd. Foamable waterless compositions with modulating agents
WO2009031642A1 (ja) 2007-09-05 2009-03-12 Pola Pharma Inc. 医薬組成物
EP2200588B1 (en) 2007-09-25 2019-03-20 Solubest Ltd. Compositions comprising lipophilic active compounds and method for their preparation
US20090253712A1 (en) 2008-04-03 2009-10-08 Semmelweis Egyetem Aqueous solvent system for solubilization of azole compounds
WO2009139925A1 (en) 2008-05-16 2009-11-19 Panacea Pharmaceuticals, Inc. Methods for the treatment of brain edema
SG173183A1 (en) 2009-02-05 2011-09-29 Targeted Delivery Technologies Ltd Methods of reducing the proliferation and viability of microbial agents
US10130610B2 (en) 2009-04-09 2018-11-20 Pola Pharma Inc. Antimycotic pharmaceutical composition
US8252821B2 (en) 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US20100280031A1 (en) * 2009-04-30 2010-11-04 Paul David Lipid formulation of apoptosis promoter
RU2734128C2 (ru) * 2010-12-16 2020-10-13 Плэтформ Брайтворкс Ту,Лтд Фармацевтические препараты азолов для парентерального введения и способы их получения и применения для лечения заболеваний, чувствительных к азольным соединениям
CN103635179B (zh) * 2011-04-28 2017-12-29 普拉福姆五金器具第二有限公司 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法

Also Published As

Publication number Publication date
PL2701684T3 (pl) 2018-09-28
AU2012250050B2 (en) 2017-04-06
ES2822350T3 (es) 2021-04-30
US20120277249A1 (en) 2012-11-01
JP2014513094A (ja) 2014-05-29
US9364433B2 (en) 2016-06-14
US11045466B2 (en) 2021-06-29
EP2701684A1 (en) 2014-03-05
AR086115A1 (es) 2013-11-20
TW201247242A (en) 2012-12-01
TWI626059B (zh) 2018-06-11
US9724345B2 (en) 2017-08-08
CN103635179B (zh) 2017-12-29
US10028949B2 (en) 2018-07-24
EP3238709B1 (en) 2020-07-01
HUE034480T2 (en) 2018-02-28
EP2701684B1 (en) 2017-06-14
IL229067B (en) 2018-03-29
HUE051400T2 (hu) 2021-03-01
US20180296556A1 (en) 2018-10-18
MX2013012579A (es) 2014-03-26
HK1245665A1 (en) 2018-08-31
CN107970209A (zh) 2018-05-01
IL229067A0 (en) 2013-12-31
US20200147076A1 (en) 2020-05-14
US10548890B2 (en) 2020-02-04
PL3238709T3 (pl) 2021-02-08
MX380805B (es) 2025-03-12
US20160346278A1 (en) 2016-12-01
DK2701684T3 (en) 2017-09-18
HK1251983A1 (zh) 2019-05-10
CN107970209B (zh) 2020-10-30
WO2012148799A1 (en) 2012-11-01
JP2017014293A (ja) 2017-01-19
CA2834262A1 (en) 2012-11-01
CN103635179A (zh) 2014-03-12
DK3238709T3 (da) 2020-09-28
JP6080312B2 (ja) 2017-02-15
AU2012250050A1 (en) 2013-11-21
CA2834262C (en) 2020-08-25
MX360638B (es) 2018-11-12
US20170172971A1 (en) 2017-06-22
EP3238709A1 (en) 2017-11-01

Similar Documents

Publication Publication Date Title
ES2640572T3 (es) Formulaciones parenterales mejoradas de agentes farmacéuticos lipófilos y procedimientos de preparación y uso de las mismas
HUE029035T2 (en) Topical formulation for a jak inhibitor
Panneerselvam et al. Dark chocolate receptors: epicatechin-induced cardiac protection is dependent on δ-opioid receptor stimulation
AU2022241458B2 (en) Use of phenoxypropylamine compounds to treat depression
WO2007132825A1 (ja) 医薬
HK1251983B (zh) 亲脂性药剂的改进的胃肠外制剂以及制备和使用其的方法
HK1193026B (en) Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
HK1193026A (en) Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
WO2024168215A1 (en) Compositions and methods for treating anhedonia
WO2021123121A1 (en) Lipid-based compositions comprising lipophilic salts and acidic ph modifiers
HK1136984B (en) Carbamoyl-cyclohexanes for treating acute mania
HK1136984A1 (en) Carbamoyl-cyclohexanes for treating acute mania